Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.
Hsin-Yi Wang, Hueisch-Jy Ding, Jin-Hua Chen...
https://pubmed.ncbi.nlm.nih.gov/23108238Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID07540260
CAIX PET/CT Guided Radiation Therapy in Clear Cell Renal Cell Carcinoma
Led by Peking University First Hospital · Updated on 2026-04-20
70
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new approach for adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). This study focuses on combining standard systemic therapy, including targeted therapy and anti-PD-1 immunotherapy, with advanced imaging and radiation techniques to better target cancer sites. The aim is to assess progression-free survival and local control of treated tumors, along with monitoring treatment-related side effects. All participants will receive dual PET/CT scans using FDG and a CAIX-targeted tracer to map cancer lesions. When possible, visible tumors identified by these scans will be treated using image-guided stereotactic ablative radiotherapy (SABR). Radiotherapy is planned to cover as many detectable lesions as feasible. This single-arm study plans to enroll about 70 patients. Participants will be followed for at least two years to evaluate how well the cancer is controlled locally and how long patients remain free from disease progression. Researchers will also track the duration of current systemic therapy until treatment changes are needed due to cancer growth. Safety and side effects related to the treatments will be monitored throughout the study period, which may last up to three years for some measures.
CONDITIONS
Brief Title
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older
- Histologically confirmed clear cell renal cell carcinoma
- Recurrent or metastatic disease
- Planned or ongoing first-line systemic therapy with targeted therapy plus anti-PD-1 immunotherapy
- Available dual PET/CT imaging (FDG PET/CT and CAIX-targeted PET/CT) and eligible for radiotherapy planning
- Multidisciplinary assessment confirms radiotherapy can treat at least 75% of detectable lesions
- Able to provide written informed consent
You will not qualify if you...
- Unable to receive stereotactic radiotherapy as planned
- Uncontrolled serious comorbidities or active infection
- Pregnant or breastfeeding
- Unable or unwilling to comply with study procedures and follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Treatment
Duration - Up to 3 years or until change of systemic therapy due to disease progression
Participants receive PET/CT guided radiation therapy planned and delivered based on imaging findings to cover detectable lesions.
Visits scheduled according to radiation therapy planning and delivery
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Loading map...
Research Team
M
Mingwei Ma
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here